These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 12809812

  • 1. 6-TG for IBD. simple, but safe?
    Tremaine WJ.
    Am J Gastroenterol; 2003 May; 98(5):950-2. PubMed ID: 12809812
    [No Abstract] [Full Text] [Related]

  • 2. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA.
    Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
    [Abstract] [Full Text] [Related]

  • 3. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine.
    Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, Teml A, Chalupna P, Stritesky J, Schoenberg SO, Schima W, Göke B, Ochsenkühn T.
    J Hepatol; 2005 Aug; 43(2):303-9. PubMed ID: 15964660
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.
    Qasim A, McDonald S, Sebastian S, McLoughlin R, Buckley M, O'Connor H, O'Morain C.
    Scand J Gastroenterol; 2007 Feb; 42(2):194-9. PubMed ID: 17327939
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
    de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkühn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ, Dutch 6-TG working group.
    Digestion; 2006 Feb; 73(1):25-31. PubMed ID: 16493198
    [Abstract] [Full Text] [Related]

  • 7. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
    Goldenberg BA, Rawsthorne P, Bernstein CN.
    Am J Gastroenterol; 2004 Sep; 99(9):1744-8. PubMed ID: 15330913
    [Abstract] [Full Text] [Related]

  • 8. Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?
    Movva R, Haywood A, Khan SA, Florin TH, Oancea I.
    J Dig Dis; 2017 Sep; 18(9):529-536. PubMed ID: 28834232
    [Abstract] [Full Text] [Related]

  • 9. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):715-29. PubMed ID: 16918876
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Walker TR, Leichter AM.
    J Pediatr Gastroenterol Nutr; 2004 Feb 01; 38(2):232-3. PubMed ID: 14974466
    [No Abstract] [Full Text] [Related]

  • 13. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
    Baker DE.
    Rev Gastroenterol Disord; 2005 Feb 01; 5(3):135-41. PubMed ID: 16127348
    [Abstract] [Full Text] [Related]

  • 14. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec 01; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 15. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun 01; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 16. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
    de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ.
    Dig Liver Dis; 2008 Feb 01; 40(2):108-13. PubMed ID: 18083079
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD.
    de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ.
    Nat Clin Pract Gastroenterol Hepatol; 2007 Dec 01; 4(12):686-94. PubMed ID: 18043678
    [Abstract] [Full Text] [Related]

  • 19. Drug therapy of inflammatory bowel disease in fertile women.
    Kroser J, Srinivasan R.
    Am J Gastroenterol; 2006 Dec 01; 101(12 Suppl):S633-9. PubMed ID: 17177868
    [Abstract] [Full Text] [Related]

  • 20. Drug interactions in inflammatory bowel disease.
    Irving PM, Shanahan F, Rampton DS.
    Am J Gastroenterol; 2008 Jan 01; 103(1):207-19; quiz 206, 220. PubMed ID: 18076738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.